Fibronectin in Immune Responses in Organ Transplant
Recipients by Coito, Ana J. et al.
Developmental Immunology, 2000, Vol. 7(2-4), pp. 239-248
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 2000 OPA (Overseas Publishers Association)
N.V. Published by license under the
Harwood Academic Publishers imprint,
part of the Gordon and Breach Publishing Group.
Printed in Malaysia
Fibronectin in Immune Responses in Organ Transplant
Recipients
ANA J. COITOa*, MARIA DE SOUSAb and JERZY W. KUPIEC-WEGLINSKIa
aThe Dumont-UCLA Transplant Center, Division ofLiver and Pancreas Transplantation, Department ofSurgery, UCLA School ofMedicine,
Los Angeles, CA 90095, USA and bThe Abel Salazar Institutefor Biomedical Sciences, 4000 Porto, Portugal
The immune response to an organ allograft involves perpetuation of T cell infiltration and
activation. Advances in understanding the mechanisms of T cell activation have placed par-
ticular emphasis on the interactions between the T-cell receptor and antigen presenting cells,
with little reference to the fact that in vivo activation occurs in the physical context of extra-
cellular matrix proteins (ECM). Indeed, the possibility that ECM proteins may have a deter-
mining role in lymphocyte adhesion and tissue localization and function is now becoming
more appreciated in view of growing evidence indicating that integrins and other T cell anti-
gens bind ECM components, with some of these components exerting synergistic effects on
T- cell activation. This review focuses on the importance of interactions between lym-
phocytes and fibronectin, a prominent ECM component, for cell migration and function in
organ allograft recipients. It explores novel therapeutic approaches based on the assumption
that fibroneetin represents an active element in the process of T cell activation in the immune
cascade triggered by organ transplantation.
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Lymphocytes recirculate between blood and lymph
until the trigger of signals that stimulate their adhe-
sion to vascular endothelium or extracellular matrix
(ECM) proteins (de Sousa et al., 1991; Springer,
1994). To emigrate through vascular endothelium,
lymphocytes have to acquire strong adhesion interac-
tions to the vessel wall while resisting to continuous
sheer forces (Diamond et al., 1994). The emerging
relevance of lymphocyte ECM interactions to cell
adhesion, migration, and positioning within specific
tissue microenvironments emphasize the role ECM
proteins may play in the functioning of the immune
system in both physiological and pathological condi-
tions (de Sousa et al., 1991).
Fibronectin (FN) is likely a key ECM protein
involved in these events. FN is a large dimeric glyco-
protein (440-500 kDa) composed of a series of inde-
pendently folding modular domains known as FN
repeats I, II, III (Hynes, 1986). These repeating units
contain regions or domains which interact with a
number of other matrix molecules as well as cells, and
mediates functions such as cell migration, matrix
assembly, differentiation, and proliferation (Yamada
et al., 1992; Hynes, 1986). Structural diversity in FN
arises by regulated alternative splicing of a single
gene transcript in three segments termed EIIIA,
EIIIB, and V in rats, and ED-A, ED-B, and IIICS
respectively in humans (Tamkun et al., 1984; Kornbli-
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htt et al., 1985). The EIIIA (or ED-A) and EIIIB (or
ED-B) domains are either included or excluded as
intact type III homology repeats. The V (or IIICS)
may be excluded, partially included, or fully included.
Alternative splicing of the FN gene allows for the
generation of multiple isoforms, with 20 isoforms
possible in humans (Schwarzbauer, 1991). The
importance ofFN in cell migration and differentiation
is underscored by the observation that mice made null
for this ECM protein die during embryonic develop-
ment (George et al., 1993; Georges-Labouesse et al.,
1996). The role of FN in lymphocyte adhesion,
migration, and activation has been illustrated in sev-
eral studies (Shimizu et al., 1990; Hauzenberger et al.,
1994; Ybarrondo et al., 1994; Ostergaard et al., 1995;
Hunter et al., 1997). Cellular adhesion to FN is medi-
ated by a superfamily of heterodimeric molecules, the
integrins (Hynes, 1987). Lymphocytes have been
shown to interact with sequences within the type III
repeats of FN primarily via two different receptors of
the 11 integrin family, the c4[1 and c5[1 (Guan, et
al., 1990; Hemler et al., 1995). Thus, 4Ill integrin,
interacts with the connecting segment-1 (CS-1),
which is located within the V region, and with a
recently described segment KLDAPT located in
FN-III5 (Moyano et al., 1997). In addition, it was
reported that the activated c4l lintegrin is also able to
interact with the RGD sequence present in the cell
adhesion domain (Sanchez-Aparicio et al., 1994).
These findings showing the flexibility of the 41]1
integrin in recognizing other domains in the FN mole-
cule, support the important role this ECM protein may
play in an array of lymphocyte biological functions.
The other main receptor for FN, the c5[1 integrin,
known to be present on a subpopulation of resting
CD45RA dim memory T cells (Klingemann et al.,
1989), interacts via the RGD sequence. Other
integrins have also been identified as alternative
receptors for FN, such as 47 (Postigo et al., 1993),
3[1 (Yamada et al., 1992), and v[l (Vogel, et al.,
1990). The adhesive capacity of integrins expressed
on circulating lymphocytes is highly regulated. Thus,
adhesion of T cells to FN has been shown to be regu-
lated by the engagement of antigen-specific
TCR/CD3 complex, as well as CD2, CD7 and CD28
(Shimizu et al., 1992; Shimizu et al., 1995; Chan et
al., 1997). The fact that TCR engagement up-regu-
lates adhesion of T lymphocytes to FN, highlights the
importance of this protein in host immune responses.
Integrin-dependent binding of lymphocytes to FN is
also regulated by a number of chemokines, including
the C-C chemokines, such as RANTES, monocyte
chemotactic protein (MCP-1) and macrophage
inhibitory protein (MIP- 1) (Weber et al., 1996; Carr
et al., 1996; Carr et al., 1994). Modifications in FN
expression may also have a regulatory role in the
integrin-mediated lymphocyte adhesion. Indeed, there
is good evidence that ECM protein binding can mod-
ulate integrin expression (LaFlamme et al., 1992;
Delcommenne et al., 1995). This review focuses on
the significance of FN expression in organ allograft
recipients, and explores novel therapeutic approaches
based on the assumption that FN is an active partici-
pant in the immune cascade leading to allograft rejec-
tion.
FIBRONECTIN IN ORGAN TRANSPLANT
RECIPIENTS
Organ allograft represents a useful in vivo experimen-
tal system to examine the role of FN in the immune
response in which the effector phase is dependent on
the migration of alloreactive cells into the foreign tis-
sue (Kupiec-Weglinski et al., 1993; Coito et al.,
1994). In our immunohistological and in situ hybridi-
zation studies of rat cardiac allografts, a markedly
increased expression of FN, mostly vascular, in the
early post-transplant period preceded cellular infiltra-
tion (Coito et al., 1994; Coito et al., 1997). This initial
up-regulation of vascular FN is a common step in
both allo- and iso- transplants and may reflect a
response to injury or ischemia that occur during the
interval of about 45 minutes of cardiac engraftment
(Coito et al., 1997). The initiation of vascular FN syn-
thesis in such an early time-point may represent an
important signal that triggers lymphocyte recruitment
at the graft site. At later time-points after allotrans-
plantation, cellular FN is predominantly expressed in
the myocardium contrasting with cardiac isografts inFIBRONECTIN IN TRANSPLANTATION 241
which myocardial FN expression is absent (Fig. 1
A&B) (Coito et al., 1997). In addition, the simultane-
ous detection of FN and laminin (LN) in cardiac allo-
grafts, by laser scanning confocal microscopy,
revealed a preferential accumulation of FN in the
interstitial areas where infiltrating mononuclear cells
(MNC) localize (Fig. 1 C&D) (Coito et al., 1994).
Similarly, sensitized lymphocytes after adoptive
transfer to test recipients localize in FN-rich areas of
both cardiac transplants (Fig 1E) and lymph nodes
(Coito et al., 1994). Moreover, treatment of rats with a
neutralizing anti-TNF- serum significantly prolongs
cardiac allograft survival, downregulates the local
production of FN and reduces intragraft MNC infil-
tration (Coito et al., 1995). All these findings support
a key role of FN to act as an in vivo adhesive factor
for lymphocytes to home to specific tissue microenvi-
ronments, including an organ transplant. Our com-
bined immunohistological and in situ hybridization
analyzes have also demonstrated that the prime
sources of FN in rejecting cardiac allografts are mac-
rophages in the myocardium and smooth muscle and
endothelial cells in the vessels (Coito et al., 1997;
Coito et al., 1995). It remains to be determined how
different cell types regtrlate FN expression in vivo.
While TGF-[ is well known to increase FN expres-
sion by fibroblasts, its role in modulating FN expres-
sion in other cell types remains unclear (Roberts et
al., 1988; Ignotz et al., 1987). Our data suggest a
potential role for TNF-c in modulating macrophage
appearance, and potentially FN expression, during
cardiac allograft rejection (Coito et al., 1995). Other
data also indicate that, in coronary arteriopathy after
transplantation, endothelial and smooth muscle cells
produced increased FN under the regulation of IL-1I
and TNF- (Clausell et al., 1993; Molossi et al.,
1995). Moreover, soluble TNF- receptor reduces the
expression of FN and leukocyte infiltration within
areas of intimal thickening (Clausell et al., 1994). In
cardiac allografts, FN exists in multiple isoforms with
a distinct temporal and spatial pattern of expression
(Coito et al., 1997). Newly synthesized FN in cardiac
grafts includes EIIIA+, EIIIB+ and CS variants that
are generated by alternative splicing of FN
pre-mRNA. The FN variants that include the EIIIA
and EIIIB segments are prominent in FN produced
during embryogenesis, and their expression in the
adult tissues is minimal unless under certain patho-
logical conditions (Vartio et al., 1987; Carnemolla et
al., 1989). For example, adult liver synthesizes the
plasma form of FN, and this form excludes the EIIIA
and EIIIB domains. However, these EIIIA and EIIIB
segments are markedly increased during cutaneous
wound healing (Brown et al., 1993; French-Constant
et al., 1989), neointimal hyperplasia (Knowlton et al.,
1992; Mamuya et al., 1992), and glomerular nephritis
(Barnes et al., 1995; Nickeleit et al., 1995). Although,
very little is known about the function of the EIIIA
and EIIIB domains of FN, by comparing the patterns
of EIIIA and EIIIB expression in cardiac allografts
and isografts, our data support the hypothesis that
these FN variants are involved in lymphocyte adhe-
sion, migration, or differentiation in cardiac allo-
grafts. Both EIIIA and EIIIB domains are highly
expressed in the myocardium of cardiac allografts
associated with increased numbers of infiltrating T
cells and appearance of infarcts. In contrast, the FN
splicing variants are not detected in the myocardium
of cardiac isografts, neither are a similar increase in T
cells, nor are infarcts. Recently, it has been shown that
EIIIA segment mediates adhesion of fibroblastic cells
and promotes the differentiation of lipocytes in the
liver to become myofibroblasts (Jarnagin et al., 1994).
We think that similar processes may be involved in
the lymphocyte biological functions in organ allo-
grafts. For example, CD8+ T-lymphocytes-mediated
lysis of target cells requires the formation of tight
conjugates between these cytotoxic T lymphocytes
and the targeted cell. While, the cellular receptors for
EIIIA and EIIIB domains are not yet fully character-
ized, the CS-1 domain recognized by the c4[1
integrin, is known to mediate lymphocyte adhesion
(Guan et al., 1990; Wayner et al., 1989). The CS-1
subunit ofFN is the first alternatively splicing domain
found to be increased in cardiac allografts, it is
up-regulated as early as at 3 hours post-transplant,
and it is preferentially expressed after day 4 (Coito et
al., 1997). The presence of specific FN variants may
provide a spatial address at which appropriated
co-stimulatory signals could initiate or augment criti-242 ANA J. COITO et al.
cal T cell signaling events. Supporting this assump-
tion, are our recent findings in rat recipients rendered
tolerant to MHC-incompatible cardiac allografts by
exogenous immunosuppressive therapy. In long-term
tolerant recipients, FN is found up-regulated in the
vessels in the absence of other vascular adhesion mol-
ecules such as VCAM-1 and ICAM-1, highlighting a
putative role for FN in the recruitment of leukocytes
at the graft site (Coito et al., 1998). Moreover, despite
the high number ofMNC infiltrating well-functioning
grafts, intramyocardial infiltrating macrophages
failed to express FN. This contrasted with long-term
control recipients undergoing chronic rejection, in
which FN expression was readily detectable in the
myocardium (Coito et al., 1998). The observation that
MNC do accumulate in the myocardium in the
absence of cellular FN in tolerant hosts, indicates
other role for this ECM protein that is unrelated to
cell migration or tissue positioning. Furthermore, by
recreating rejection in tolerant hosts, we have pointed
out a novel role for FN in the upregulation of IL-2 and
IFN-y expression, indicating that FN by itself may
play an active role in cellular activation (Coito et al.,
unpublished). Our results are consistent with the con-
cept that FN exerts synergistic effects on T cell acti-
vation by acting as a co-stimulator for both CD4+ and
CD8+ T cells through TCR (Ostergaard et al., 1995;
Matsuyama et al., 1989) and cytokine release. For
example, the density of immobilized CD3 or TCR
mAb required to induce degranulation and tyrosine
phosphorylation of cellular proteins by CD8+ T cells
is about 10-fold lower in the presence of FN (Oster-
gaard et al., 1995). Several studies have also shown
that adhesion to FN activates tyrosine phosphorilation
of several T cell proteins (Ostergaard et al., 1995;
Nojima et al., 1992; Ticchioni et al., 1995). The pro-
duction of IL-2, IFN-y, and TNF are also stimulated
in vitro by interactions between CD4+ cells and FN
(Yamada et al., 1991; McCarthy et al., 1997; Brun-
mark et al., 1997; Hershkoviz et al., 1993). Moreover,
it has been reported that the binding of CD4+ cells to
ECM proteins, most likely through conformational
changes resulting in better presentation to their recep-
tor, may in turn enhance cytokine activity (Crawford
et al., 1998; Lortat-Jacob et al., 1991; Lortat-Jacob et
al., 1991). Taken together, these findings support the
idea that FN is an active participant in the immune





That MNC-FN disturbed in vivo adhesive interactions
play immunopathological role, and may represent
important targets for novel therapeutic interventions,
has been documented in both autoimmune disease
and transplantation animal models. Multiple-organ
MNC infiltration occurs in TGF-[I knockout mice,
followed by cachexia, and death (Hines et al., 1994).
In addition, cells from TGF- deficient mice exhibit
increased adhesion to FN matrices in vitro. Such an
increased adhesion in culture has been inhibited fol-
lowing incubation of cells with synthetic FN peptides
that interact with integrins (RGD/CS-1) and/or cell
surface proteoglycans (C/H-I/II/III/V). Interestingly,
daily systemic injections of FN peptide preparations
virtually blocked leukocyte tissue sequestration, and
the development of autoimmune-like lesions, and
retarded the lethal wasting syndrome characteristic
for this model. The efficiency of FN peptides has
been also documented in the rat model of erosive pol-
yarthritis (Wahl et al., 1994). Not only were FN pep-
tides inhibitory to acute and chronic synovial
pathology, but were also found to prevent and reverse
local recruitment, and the evolution of arthritis.
Our own data are consistent with the model in
which in vivo interactions between the 4[ integrin
receptor and the cell-associated CS 1 motif of FN are
critical in the acute allograft rejection cascade (Coito
et al., 1998). Indeed, treatment of rat recipients of car-
diac allografts with a 7 day course of bioactive CS-1
peptides: (i) abrogated acute rejection, and doubled
the transplant survival time, (ii) diminished vascular
expression of adhesion molecules such as VCAM-1
and ICAM-1, (iii) reduced intragraft infiltration by
CD4+ and CD8+ cells, and (iv) decreased allo-Ag
activation at the graft site, as evidenced by decreasedFIBRONECTIN IN TRANSPLANTATION 243
FIGURE FN and infiltrating MNC in cardiac transplants. Immunofluorescence localization of cellular FN is shown in cardiac allograft (A)
and isograft (B) at day 6 post-transplant. In cardiac allografts, cellular FN (white) is detected in elevated amounts in both myocardium and
epicardium; in cardiac isografts cellular FN is restricted to the epicardium (arrow) but absent from the myocardium. Simultaneous detection
of FN and laminin (LN) in rejecting cardiac allograft by confocal microscopy (C) shows a preferential accumulation ofFN in the interstitial
areas where infiltrating MNC localize (D). The yellow around the myocytes represents mixed deposition of FN and LN; the green in the
interstitial areas represents exclusively FN deposits. Panel D shows monocyte/macrophages stained in brown by immunoperoxidase. Panel E
illustrates the immunohistologic localization in a cardiac allograft of specifically sensitized lymph node lymphocytes labeled in vitro with Di
’T’ in red after adoptive transfer. As documented by confocal microscopy, labeled red cells are detected in association with FN deposits
(stained in green) at the graft site. Original magnification 109 (A, B); 400 (C); 230 (D); and 1200 (E) (see Color Plate XIV at the back
of this issue)244 ANA J. COITO et al.
infiltration by CD25+ cells, and diminished expres-
sion of Thl and Th2 type cytokines. These immuno-
suppressive effects could be reversed and acute
rejection recreated after adjunctive treatment with
recombinant IL-2, suggesting that CS1 peptides may
induce a temporary state of cytokine-responsive T
cell anergy, in vivo.
Most of the adhesion functions mediated by 41
integrin are attributed to interactions with its two
known ligands, the CS1 motif in the FN molecule,
and VCAM-1 expressed on endothelial cell surfaces.
Although it is possible the CS 1 peptide may interfere
with c41 VCAM- interactions, c41 has been
shown to have distinct ligand/binding sites for
VCAM-1 and FN (Elices et al., 1990), suggesting that
the CS peptide that binds to VLA-4 does not likely
inhibit the binding by VCAM-1. Moreover, although
VCAM-1 and CS1-FN may share spatially overlap-
ping biding sites on 41, the concentration of FN
peptides that interfere with the 41 VCAM-1
binding are several-fold higher than those required for
the c41 CS blockade (Makarem et al., 1994).
Hence, it seems quite unlikely that the effects of rela-
tively low dose CS peptide regimen upon the kinet-
ics of, and local cell recruitment associated with acute
graft rejection, could be attributed to the blockade of
c4[ 1 VCAM-1 interactions. Supporting this notion
are findings from mouse cardiac transplant models of
persistent T cell infiltration in allografts despite
anti-VCAM-1 mAb therapy, and transient T cell infil-
trate in isografts, which are devoid of VCAM-1
expression (Orosz et al., 1993). These strongly sug-
gest a role for VCAM-l-independent collateral sys-
tem(s) that mediate leukocyte sequestration during
the course of acute graft-deteriorating rejection. It has
been shown that the blockade of c4[1-dependent leu-
kocyte endothelial adhesive interactions by treat-
ment with anti-VLA-4 mAb (TA-2) was insufficient
to delay acute rejection of pancreatic islets in rat
recipients (Brown et al., 1993). In contrast to the
blockade of c4[1 FN interactions by CS 1 peptides,
the protective effects afforded by targeting the 41
integrin by mAb alone are rather short-lived, and
insignificant upon allo-Ag-driven mononuclear and
endothelial cell activation leading to graft rejection in
transplant recipients. However, in a more recent
study, administration of CS 1 peptides to mice recipi-
ents of islet allografts not only abrogated graft rejec-
tion, but also prevented graft infiltration, suggesting a
role for c4/FN interactions in leukocyte homing to
the graft site (Stegall et al., 1999).
We have also tested the efficacy of CS-1 peptides
in presensitized rat recipients in which therapy with
rapamycin (RPM) abrogates rejection at 24h, but it
does not prevent the ultimate cardiac allograft loss at
40-50 days (Korom et al., 1998). These long-term
grafts show progressive development of arteriosclero-
sis, a hallmark of chronic rejection (Wasowska et al.,
1996). Indeed, an adjunctive course of CS-1 peptides
in the early post-transplant phase resulted in the dis-
appearance of the inflammatory and smooth muscle
Cells from the arterial intimal of long-term recipients.
Unlike medium or large arteries in rats undergoing
monotherapy, those foowing adjunctive CS-1 pep-
tides had normal internal elastic laminea, and were
free of neointimal thickening, confirming that CS-1
peptides successfully prevented the development of
arterial chronic injury. Moreover, treatment with CS 1
peptides reduced gene transcript and product levels
for T cell- and macrophage- derived cytokines and
chemoattractants, which are known to contribute to
the development of progressive chronic-type allograft
failure. A similar finding was observed in a choles-
terol-fed rabbit model in which treatment with CS-1
peptides specifically blocked vascular changes, and
markedly diminished accelerated coronary arteriopa-
thy (Molossi et al., 1995). Therapy with FN peptides
effectively depressed intragraft transendothelial infil-
tration by macrophages and T cells, documenting the
functional role of FN in the trafficking of inflamma-
tory cells in progression of cardiac arteriopathy. How-
ever, unlike in our rat study, CS1 peptides did not
affect the grade of cardiac rejection in the rabbit
model, as judged by the extensive myocardial cell
infiltration, myocyte necrosis, hemorrhage, and fibro-
sis. As integrin- FN interactions are critical for T cell
activation, adhesion, and local retention to perpetuate
chronic inflammatory responses, antagonism of cellu-
lar activation, and recruitment by FN peptides pro-
vides an important mechanism for modulating theFIBRONECTIN IN TRANSPLANTATION 245
multi-step adhesion process, and attenuating aberrant
inflammatory responses (Rodriguez et al., 1992).
Given the efficacy ofFN peptides to block neointimal
thickening in coronary vessels, this novel therapy
may interfere with the migration of smooth muscle
cells from the media into the intima, with resultant
reduction of neointimal hyperplasia, consistent with
the expression of 4131 integrin by smooth muscle
cells (Molossi et al., 1995). In addition to regulating
cell growth and differentiation, FN may also function
as a lymphocyte survival factor in cardiac allografts.
Indeed, there is a growing body of evidence that
anchorage-dependent cells when prevented from
attaching to ECM proteins may undergo apoptosis
(Meredith et al., 1993; Boudreau et al., 1995; Sethi et
al., 1999).
The CS 1-mediated prevention of chronic rejection
may result from a far more reaching effect on
long-term in vivo interactions between MNC,
endothelial vascular lining and the ECM scaffolding.
Treatment with RPM abrogates rejection in presensi-
tized hosts by depressing humoral and T cell cyto-
toxic and proliferative responses (Wieder et al., 1993;
Schmidbauer et al., 1994). At this point, host-vs-graft
interactions are limited’to the cellular contact with
ECM and the endothelial lining. Adjunctive adminis-
tration of CS1 peptides during this early post-trans-
plant phase may impair the engagement of T cells
with FN as part of the transplant structural frame-
work. At the same time, CS1 peptides may modify
intragraft vasculature by reducing its adhesiveness for
host leukocytes. During the ensuing maintenance
phase, the alterations in intragraft MNC homing and
positioning are mimicked by the prevailing macro-
phage response. The perpetual cycle of late macro-
phage-associated proinflammatory mediators, smooth
muscle proliferation, neointimal formation, and sub-
sequent vasculature occlusion fails to be initiated.
Collectively, these data advance the hypothesis that
local synthesis of FN is an ongoing feature of, and
adhesive FN MNC associations are critical for the
development of acute and chronic rejection in trans-
plant recipients. Further elucidation of FN- MNC
interactions may ultimately offer potential novel sites
for intervention in the control of transplant rejection,
and may lead to the development of refined strategies
based upon new concepts of host immunomodulation.
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